Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. Such companies are often building obstacles to access, such as high expense restrictions and PA that hinder user availability. Industry indicate… Read More